Report Store Get Proposal

Home Blog Oncology

Oncology

pharma-news-for-sanofi-lilly-roche

Notizia - Recent Pharma, Healthcare and Biotech Happenings

Sanofi Advances wAIHA Program as Rilzabrutinib Receives Breakthrough and Orphan Status; Lilly Moves to Acquire Orna Therapeutics, Expanding Cell Therapy Portfolio; Roche Announces Key PPMS Trial Success for Fenebrutinib; Priovant’s Brepocitinib Demonstrates Strong Potential in Phase 2 Cutaneous Sarcoidosis Study; AstraZeneca’s DATROWAY Grants US Priority Review for 1L mTNBC Indication in Patients not Eligible for Immunotherapy

Sanofi’s Rilzabrutinib Granted Breakthrough and Orphan Designations for wAIHA Rilzabrutinib (WAYRILZ) by Sanofi (EPA: SAN) recently achieved two major regulatory milestones: FDA Breakthrough Therapy Designation in the U.S. and Orphan Drug Designation by the Japanese Ministry of Health, Labour and Welfare for the treatment of warm autoimmune hemolytic anemia (wAIHA). wAIHA is a rare, life-threatening autoimmune disorder where the immune system incorrectly identifies red blood cells as foreign and destroys them, primarily in the spleen and liver. This leads to profound anemia, fatigue, and potential cardiovascular failure. Currently, the standard of care relies on co...

Explore More...

menin-inhibitors-for-acute-leukemia

Menin Inhibitors: A Revolutionary Treatment Paradigm for Acute Leukemia

medtech-news-for-ge-healthcare-oracale-life-sciences-revbio

GE HealthCare Secures FDA 510(k) Clearance and CE Mark for Allia Moveo, Completing First Global Installation; China NMPA Approves Promega’s MSI Test as a Companion Diagnostic for KEYTRUDA; Oracle Life Sciences AI Data Platform Unifies Data and Agentic Intelligence to Accelerate Breakthroughs and Boost Commercial Outcomes; Quest Diagnostics Launches New Blood Test for Detecting Minimal Residual Myeloma; RevBio Secures FDA Clearance to Begin Pivotal Study of Cranial Bone Glue; Hyperfine Reports Breakthrough Clinical Findings on Swoop® System’s Increased Sensitivity in Stroke Detection

major-nanomedicine-applications

Top 8 Applications of Nanomedicine in Healthcare

pharma-news-for-sanofi-corcept-corxel

Sanofi Strengthens Amlitelimab’s Position in Atopic Dermatitis; Corcept Announces Statistically Significant Overall Survival Benefit in Phase 3 ROSELLA Study; CORXEL Raises $287M Series D1 for Cardiometabolic Pipeline Expansion; IntraBio’s Levacetylleucine Demonstrates Positive Results in Pivotal Ataxia-Telangiectasia Trial; Otsuka Secures FDA Acceptance and Priority Review for Centanafadine in ADHD

jpm-healthcare-2026-highlights

JPM 2026 Recap: Who’s Winning, Who’s Catching Up, and Who’s at Risk?

pharma-news-for-nxera-astrazeneca-abbvie

Nxera Pharma Confirms Positive Phase 3 Findings for Daridorexant in South Korea; AstraZeneca Strengthens Oncology Pipeline in China With GPC3 Armored CAR-T Rights From AbelZeta; AbbVie Shares Topline Findings from Phase 3 EPCORE DLBCL-1 Study of Epcoritamab; ImmunityBio Achieves Prolonged Complete Response Using Chemotherapy-Free CD19 CAR-NK Platform; Sobi Wins EU Approval for ASPAVELI to Treat C3G and Primary IC-MPGN

emering-cancer-cachexia-drugs

Cancer Cachexia Drug Landscape Heats Up with Multiple Assets Advancing—7 Therapies to Watch Out

rise-of-dll3-targeted-therapies-in-neuroendocrine-cancers

Is DLL3 Unlocking the New Code for the Neuroendocrine Cancers (NECs) Therapeutics’ Era?

pharma-news-for-novo-windward-astrazeneca

Novo Nordisk Gains US Approval for Oral WEGOVY; Windward Bio Strengthens Immunology Pipeline With Clinical-Stage Bispecific WIN027; US FDA Grants Breakthrough Therapy Designation to ENHERTU in the Post-neoadjuvant Setting for HER2-positive Early Breast Cancer; Ipsen Enhances Early R&D Pipeline via Simcere Zaiming ADC; Roche Secures FDA Approval for SC Lunsumio VELO in Follicular Lymphoma

leptomeningeal-metastases-treatment-void

Leptomeningeal Metastases Treatment Challenge: High Burden, Zero Approvals

enhertu-for-metastatic-her2-breast-cancer

ENHERTU Plus Pertuzumab Approved in Breast Cancer: First New First-Line Option in Over a Decade

ai-driven-medical-imaging

The Automated Eye: How AI-Driven Diagnostics are Reshaping the Future of Medical Imaging

pharma-news-for-pilatus-astrazeneca-sanofi

Pilatus Biosciences Advances PLT012 Into the Clinic Following FDA IND Clearance; ENHERTU + pertuzumab Receives US Approval as the First New First-line Option in a Decade for HER2-positive Metastatic Breast Cancer; Sanofi Reports on Tolebrutinib Development in Primary Progressive MS; Gilead Reports Positive Phase 3 Results for Bictegravir–Lenacapavir Investigational HIV Therapy; argenx Announces Study Update for UplighTED Program of Efgartigimod SC in Thyroid Eye Disease

medtech-news-for-bendit-proverum-medint

Bendit Received FDA Clearance for the Bendit17™ Steerable Microcatheter; ProVee System Receives FDA Approval as a New-Era Prostatic Urethral Stent for BPH; a2z Radiology AI Secures $4.5M Seed Funding to Advance Full-Spectrum CT Analysis; MedINT Introduces Advanced Medical AI System Integrating Clinician Oversight; Nitinotes Treats First Patient in Pivotal EASE™ Trial of the EndoZip™ Automated Suturing System for ESG; Airiver Medical Secures FDA IDE Authorization to Launch Pivotal CRS Clinical Trial

anti-gpc3-targeted-therapies-in-oncology

Evolving Landscape of Anti-GPC3 Targeted Therapies: ADCs, CAR-T Cells, and Beyond

metastatic-colorectal-cancer-drugs-in-development

The Next Wave of Metastatic Colorectal Cancer Drug Treatment: 6 Therapies Poised to Change the Landscape

Subscribe to our Updates

DelveInsight is dedicated to safeguarding your data. We ensure that your information is handled in compliance with relevant data privacy legislation, our internal guidelines, and our privacy policy.

Receive recent Healthcare updates directly in your inbox.

Daily

Weekly

Monthly